论文部分内容阅读
目的观察尤瑞克林联合依达拉奉治疗急性脑梗死对患者血清白介素-6(IL-6)、胱抑素(Cys-C)、肿瘤坏死因子-α(TNF-α)水平的影响。方法将200例急性脑梗死患者随机分为研究组和对照组各100例。研究组在常规治疗基础上加用尤瑞克林联合依达拉奉治疗,对照组在常规治疗基础上仅加用依达拉奉治疗。观察2组患者治疗前后血清IL-6、Cys-C、TNF-α水平。结果治疗前2组血清IL-6、Cys-C、TNF-α水平差异均无统计学意义(P>0.05),治疗后2组患者各指标水平均较治疗前降低(P<0.05),且治疗后研究组血清各指标水平均低于对照组(P<0.05)。结论尤瑞克林联合依达拉奉对急性脑梗死患者进行治疗可更有效地降低血清IL-6、Cys-C、TNF-α水平。
Objective To observe the effect of uracil combined with edaravone on the serum levels of interleukin-6, cystatin C and tumor necrosis factor-α (TNF-α) in patients with acute cerebral infarction. Methods 200 cases of acute cerebral infarction were randomly divided into study group and control group of 100 cases. The study group plus uracil combined edaravone on the basis of conventional treatment, the control group on the basis of conventional treatment with edaravone therapy alone. The levels of serum IL-6, Cys-C and TNF-α in two groups before and after treatment were observed. Results There was no significant difference in the levels of serum IL-6, Cys-C and TNF-α between the two groups before treatment (P> 0.05). After treatment, the levels of IL-6, After treatment, the serum levels of each study group were lower than the control group (P <0.05). Conclusion The combination of uracil and edaravone in patients with acute cerebral infarction can effectively reduce the levels of serum IL-6, Cys-C and TNF-α.